Report Back from SABCS 2023: Spotlight on the Latest in MBC
Today we are bringing you a special episode that we created in partnership with SHARE Cancer Support. It’s an audio version of a live webinar that was done this past February called Report Back from San Antonio Breast Cancer Symposium 2023. SABCS is the world’s leading breast cancer research meeting where scientists, patient advocates, and others dedicated to working in the field of cancer gather. In this podcast, Dr. Timothy Pluard highlighted promising research, targeted therapy, the evolving treatment after CDK 4/6 inhibitors, liquid biopsy and more.
Understanding Progression: How to Identify & Treat ESR1 Mutations in HR+ MBC
Today we are bringing you a special podcast that we created in partnership with SHARE Cancer Support called Understanding Progression: How to Identify and Treat ESR1 Mutations in HR+ MBC. This episode was produced from a live webinar from this past October. There has not been a new endocrine treatment in decades and many of us find out the endocrine treatment no longer works for us because the cancer has mutated. Kate Vieira Pfitzer and Victoria Goldberg are excited to bring Dr. Virginia Kaklamani to you. You will hear her explain this common problem, how to test for it, the new treatment option that is now available as well as many of the ongoing clinical trials for HR+ MBC.
Report Back From ASCO 2023: What’s the Latest News in MBC Research?
Dr. Sherry Shen, breast oncologist from Memorial Sloan Kettering Cancer Center, breaks down the recent research from the American Society of Clinical Oncology (ASCO) 2023 Annual Meeting. She will present new findings in Metastatic Breast Cancer research.
OMBCL Shorts #2: Dr. Erika Hamilton with Top Takeaways from ASCO23
Our second OMBCL Shorts features Dr. Erika Hamilton answering questions about her top takeaways from ASCO23. In this 20-minute interview we covered important updates on the CDK4/6 inhibitors for both early-stage and metastatic breast cancer, as well as research on a new HER3 ADC and the first AKT inhibitor for MBC.
OMBCL Shorts #1: Dr. Stephanie Graff & Her Steps For Those Newly Diagnosed MBC
Our inaugural OMBCL Shorts features Dr. Stephanie Graff talking about what she does when someone is newly diagnosed with MBC. This season, we had a 3-part series for people newly diagnosed and we couldn't resist getting her take on the topic. And we're so glad we asked!
Recent Advances, Controversies, and Emerging Trends in MBC
Over the last 20 years, advances in HER2 targeting treatments, antibody-drug conjugates (ADCs), immune checkpoint inhibitors (ICIs), and cyclin-dependent kinase 4 and 6 inhibitors (CDK4/6is) have prolonged survival and changed the breast cancer treatment landscape. Success leads to more questions about optimal drug sequencing, mechanisms of resistance, and how to overcome that resistance. Let’s ask Dr. Stephanie Graff to help us tackle these topics and more.
2022 in Review: Best in MBC with Dr. Erika Hamilton
Welcome to the first Road to A Cure episode of Season 6. Our guest is the incomparable Dr. Erika Hamilton, a breast oncologist and researcher who, as she says herself, doesn’t shy away from difficult questions. In this episode, we get a review—subtype by subtype—of the biggest news over the past 15 months. Of course, we also talk about what is on the horizon in MBC.
ASCO 2022: When The Dust Settles, What Are My Treatment Options For ER+/HER2- MBC?
Welcome to the second part of our post–2022-ASCO analysis of the state of affairs in the HR-positive MBC. It was not so long ago that our only options were single-agent endocrine therapy and systemic chemo. We have come a long way over the last couple of decades. Today we are asking Drs. Stephanie Graff, Sara Hurvitz, and Kevin Kalinsky to talk about how they make decisions in the clinic in selecting and sequencing treatments, specifically CDK4/6 inhibitors and the newly approved targeted therapies.
RTAC: FES/Cerianna Screening for Estrogen Positive MBC
There’s a FDA- approved diagnostic imaging agent developed to comprehensively evaluate estrogen receptor-positive (ER+) lesions in recurrent or metastatic breast cancer as an adjunct to biopsy. By creating a “whole-body” picture of ER+ lesions, Cerianna may be a helpful diagnostic tool in helping oncologists better determine the most appropriate course of treatment. Learn more in this episode.
ASCO 2022: When the Dust Settles, Will ADCs Change MBC?
While HER2-Low and DESTINY-Breast04 garnered most of the headlines from the ASCO 2022 in June, it was not the only reason for optimism. Our MBC Life takes a deeper dive with Dr. Stephanie Graff and Dr. Hope Rugo in this first episode of our two-part series.
Dr. Shanu Modi: How to Get a Standing Ovation at ASCO?
MSK’s Dr. Shanu Modi, lead investigator on the DESTINY-Breast04 trial, talks with the Our MBC Life team about the trial’s standing ovation at ASCO, how to know if we’re HER2-low, and what this all means for us.
MBC101: The HER2-Low Show
The DESTINY-Breast04 trial at ASCO 2022 introduced many people to the term “HER2-low.” But how do you know if you’re HER2-low? In this episode, with the help a breast pathologist and a clinical oncologist we dive into this subtype and what it means to us.
Report Back from ASCO 2022: What’s the Latest in MBC Research?
The biggest cancer conference in the world, the American Society of Clinical Oncology (ASCO) 2022 annual meeting, was back in person after 2 years online during the COVID pandemic. Some of the research highlights presented this year are “practice-changing.” and received a rarely given standing ovation. What is practice changing in MBC? Get the answer to this question and a lot more in the report back from ASCO
Healing our Distress: The Potential of Psilocybin-assisted Therapy
Welcome to our series on the potential of psilocybin-assisted therapy to help us live as well as possible with metastatic breast cancer.
In this first episode, co-host and producer of this series, Dr. Paula Jayne and co-host Lynda Weatherby interview Dr. Boadie Dunlop, Director of the Mood and Anxiety Disorders Program at Emory University. Dr Dunlop shares existing and emerging data on how psilocybin may help those of us living with MBC and discusses an upcoming pilot trial of psilocybin-assisted therapy at Emory University’s Palliative and Supportive Care Clinic.
Dr. Nancy Lin: Are CNS Mets Becoming More Treatable? What’s New with STOP-HER2?
Brain metastases are unfortunately an all too common and devastating complication of breast cancer. The blood-brain barrier has long been a key obstacle to developing effective systemic therapies; however, newer agents are showing signs of overcoming this challenge. Dr. Nancy Lin explains.
ER Progression and Resistance: Causes, Consequences, and Hope
Endocrine therapy is an effective way to treat hormone-sensitive breast cancers, but de novo and acquired resistance to this treatment remains a major challenge. In this episode, the Our MBC Life team hears from two dynamic MSK oncologists Dr. Pedram Razavi and Dr. Komal Jhaveri on treatment strategies and the latest research around the problem of endocrine resistance.
Dr. Stephanie Graff: Understanding Progression
What does it mean when our cancer shows progression? And how do we know when that happens? The Our MBC Life team gets the lowdown from Dr. Stephanie L. Graff.
Doing End-Of-Life Right
How does one do things right at the end of life? There are many ways to answer this question, as varied as all of us.
Dr. Priya Kumthekar: Glimpses of Hope for Leptomeningeal Metastases
Co-hosts Victoria Goldberg and Dr. Paula Jayne sit down with neuro-oncologist Dr. Priya Kumthekar to talk about leptomeningeal metastases: what they are, how are they treated, and what research is upcoming, including a discussion on ANGled, the new Phase 3 trial for MBC patients newly diagnosed with leptomeningeal metastases.